Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer

详细信息    查看全文

• 作者：H. Pluchart ; E. Jacquet ; D. Charlety ; B. Allenet ; P. Bedouch…
• 刊名：Targeted Oncology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：11
• 期：5
• 页码：687-691
• 全文大小：1,182 KB
• 刊物主题：Oncology; Biomedicine general;
• 出版者：Springer Paris
• ISSN：1776-260X
• 卷排序：11

文摘

We report the case of a woman with metastatic breast cancer receiving intrathecal trastuzumab (and intravenous trastuzumab for more than 7 years). She was diagnosed in 2001 with a duct invasive breast cancer T3N1M0 HER2 (human epidermal growth factor receptor 2)-positive +++ HR (hormone receptor) -negative. She received chemotherapy and then she had a mastectomy. Several metastases were discovered and treated from 2003 to 2008 with chemotherapy. In March 2010, brain metastases and a leptomeningeal carcinomatosis from her HER2-positive breast cancer appeared. From that moment on she received intravenous trastuzumab (6 mg/kg) every 3 weeks, intrathecal trastuzumab (21 mg) weekly for 16 injections and lapatinib. Intrathecal trastuzumab was stopped because of cerebrospinal fluid (CSF) clearing. Intrathecal trastuzumab was injected again from December 2013 for 14 injections. The relevance of treating leptomeningeal carcinomatosis with intrathecal trastuzumab administration is shown through this case report.References1.Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(1):92–8.CrossRefGoogle Scholar2.Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.CrossRefPubMedGoogle Scholar3.Dumitrescu C, Lossignol D. Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature. Case Rep Oncol Med. 2013;2013:154674.PubMedPubMedCentralGoogle Scholar4.Gutierrez M, Lyazidi S, Brasseur L, Cvitkovic F, Le Scodan R. Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment? Bull Cancer (Paris). 2011;98(4):417–24.Google Scholar5.Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008;19(11):1978–80.CrossRefGoogle Scholar6.Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(11):2349–51.Google Scholar7.Stemmler H-J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs. 2007;18(1):23–8.CrossRefPubMedGoogle Scholar8.Cooper PR, Ciambrone GJ, Kliwinski CM, Maze E, Johnson L, Li Q, et al. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Res. 2013;1534:13–21.CrossRefPubMedGoogle Scholar9.Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, et al. Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014.10.Stemmler H-J, Mengele K, Schmitt M, Harbeck N, Laessig D, Herrmann KA, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs sept. 2008;19(8):832–6.CrossRefGoogle Scholar11.Lombardi G, Zustovich F, Farina P, Della Puppa A, Manara R, Cecchin D, et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist. 2011;16(8):1175–88.CrossRefPubMedPubMedCentralGoogle Scholar12.Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lässig D, et al. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep. 2006;15(5):1373–7.PubMedGoogle Scholar13.Oliveira M, Braga S, Passos-Coelho JL, Fonseca R, Oliveira J. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat. 2011;127(3):841–4.CrossRefPubMedGoogle Scholar14.Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer Oxf Engl 1990. 2004;40(18):2726–33.Google Scholar15.Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21(11):2183–7.CrossRefGoogle Scholar16.Rudnicka H, Niwińska A, Murawska M. Breast cancer leptomeningeal metastasis--the role of multimodality treatment. J Neurooncol. 2007;84(1):57–62.CrossRefPubMedGoogle Scholar17.Baculi RH, Suki S, Nisbett J, Leeds N, Groves M. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(13):3297–8.Google Scholar18.Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat. 2013;139(1):13–22.CrossRefPubMedGoogle ScholarCopyright information© Springer International Publishing Switzerland 2016Authors and AffiliationsH. Pluchart1Email authorView author's OrcID profileE. Jacquet2D. Charlety1B. Allenet341P. Bedouch341M. Mousseau21.CHU Grenoble, Pôle PharmacieGrenobleFrance2.Pôle cancérologie médecine aigüe communautaire, Unité d’oncologie médicale, CHU GrenobleGrenoble cedex 9France3.Université Grenoble Alpes, TIMC-IMAGGrenobleFrance4.CNRS, TIMC-IMAGGrenobleFrance About this article CrossMark Print ISSN 1776-2596 Online ISSN 1776-260X Publisher Name Springer International Publishing About this journal Reprints and Permissions Co-published with